Dennis L Andress, 727933 E Soaring Eagle Way, Scottsdale, AZ 85266

6369029, Apr 9, 2002

Jun 2, 1995

08/456640

Dennis L. Andress - Seattle WA, 98112
Michael C. Kiefer - Clayton CA

Chiron Corporation - Emeryville CA
Dennis L. Andress - Seattle WA

A61K 3818

514 12, 514 2, 530399

Methods for stimulating osteogenesis using C-terminally truncated insulin-like growth factor binding protein-5 (IGFBP-5) compounds and derivatives thereof are described. The IGFBP-5 polypeptides used in the methods are mitogenic and can be combined in compositions with insulin-like growth factor (IGF).

6391588, May 21, 2002

Jun 2, 1995

08/460221

Dennis L. Andress - Seattle WA, 98112
Michael C. Kiefer - Clayton CA

Chiron Corporation - Emeryville CA
Dennis L. Andress - Seattle WA

C12N 1516

435 694, 435 697, 435 703, 435 711, 435243, 4352551, 435358, 536 234, 536 2351

Purified compounds comprising truncated insulin-like growth factor binding protein (IGFBP) capable of binding to an antibody specific for the compound or to an insulin-like growth factor wherein the truncated IGFBP has a decreased affinity for insulin-like growth factors (IGFs) are described. Recombinant DNA molecules encoding the truncated IGFBPs are also described along with recombinant microorganisms and cell lines containing the DNA molecules and methods for producing the truncated IGFBPs using recombinant hosts containing the relevant DNA molecules. Methods for stimulating mitogenic activity and also for treating a bone disorder in mammals are also described.

6489294, Dec 3, 2002

Jun 2, 1995

08/458658

Dennis L. Andress - Seattle WA, 98112
Michael C. Kiefer - Clayton CA

Chiron Corporation - Emeryville CA
Dennis L. Andress - Seattle WA

A61K 3818

514 12, 514 2, 530399

Purified C-terminally truncated insulin-like growth factor binding protein-5 (IGFBP-5) compounds are described. The compounds are mitogenic and bind to insulin-like growth factors (IGFs) with decreased affinity. The C-terminally truncated IGFBPs can be produced recombinantly.

2002014, Oct 3, 2002

Oct 24, 2001

10/001913

Dennis Andress - Seattle WA, US

A61K038/30

514/012000

Methods of enhancing bone formation and/or bone accretion in vivo are disclosed. The methods utilize IGFBP-5 polypeptides, including full-length IGFBP-5, analogs or fragments thereof. These molecules can be delivered alone or in combination with agents which inhibit bone resorption or additional agents that enhance bone accumulation.

2016012, May 12, 2016

Nov 6, 2015

14/934577

- North Chicago IL, US
Hiddo J. Lambers Heerspink - Groningen, NL
Dick de Zeeuw - Groningen, NL
Blai Coll - Highland Park IL, US
Dennis Andress - Chicago IL, US

A61K 31/4025

The disclosure relates to methods of treating chronic kidney disease and diabetic nephropathy using predictors of fluid retention to minimize the risk of adverse events. The methods disclosed are particularly useful in treatments involving endothelin receptor antagonists, and more particularly, atrasentan and pharmaceutically acceptable salts thereof.

2016007, Mar 17, 2016

Apr 30, 2014

14/888195

- Chicago IL, US
Dennis ANDRESS - Chicago IL, US
Peter J. BRENNAN - Libertyville IL, US
James C. STOLZENBACH - Buffalo Grove IL, US

Abbvie Inc. - North Chicago IL

A61K 31/4025
A61K 45/06

The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.